Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

Blockhead11-26

Tuesday's IBD 50 Stocks To Watch pick is biotech stock ADMA Biologics (ADMA), which is back above a recent buy point. ADMA stock is also the No. 1-ranked stock on the IBD 50 list, which makes it one ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486004585?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2018/11/stock-DNA-03-adobe-150x150.jpg","is_english":true,"pubTime":"2024-11-26 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486004585","market":"sg","top_or_hot":-1,"title":"Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge","media":"Blockhead","content":"<div>\n<p>Tuesday's IBD 50 Stocks To Watch pick is biotech stock ADMA Biologics (ADMA), which is back above a recent buy point. ADMA stock is also the No. 1-ranked stock on the IBD 50 list, which makes it one ...</p>\n\n<a href=\"https://www.investors.com/research/adma-stock-buy-point/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 22:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/research/adma-stock-buy-point/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tuesday's IBD 50 Stocks To Watch pick is biotech stock ADMA Biologics (ADMA), which is back above a recent buy point. ADMA stock is also the No. 1-ranked stock on the IBD 50 list, which makes it one ...</p>\n\n<a href=\"https://www.investors.com/research/adma-stock-buy-point/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0256863902.USD","symbol_name":"ALLIANZ US EQUITY \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.investors.com/research/adma-stock-buy-point/","article_id":"2486004585","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/11/stock-DNA-03-adobe-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486004585","pubTimestamp":1732632698,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","ADMA":"ADMA Biologics Inc","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","RYTM":"Rhythm Pharmaceuticals Inc.","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1935042215.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC A","IE00BYXW3230.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"AA\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","ATAT":"亚朵","LU2097344431.USD":"SCHRODER ISF SUSTAINABLE MULTI-ASSET INCOME \"A\" (USDHDG) INC","NVD":"GraniteShares 2x Short NVDA Daily ETF","BK4543":"AI","NVDD":"Direxion Daily NVDA Bear 1X Shares","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","NVDS":"Tradr 1.5X Short NVDA Daily ETF","3NVD.UK":"LS 3X NVIDIA","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","NVDU":"Direxion Daily NVDA Bull 2X Shares","NVD2.UK":"2X NVIDIA ETP","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","2NVD.UK":"2X NVIDIA ETP","NVDX":"T-REX 2X LONG NVIDIA DAILY TARGET ETF","LU0234572021.USD":"高盛美国核心股票组合Acc","SNVD.UK":"LS -1X NVIDIA","NVD3.UK":"LS 3X NVIDIA","LU1815336760.USD":"THREADNEEDLE (LUX) GLOBAL TECHNOLOGY \"AUP\" (USD) INC","NVDY":"YIELDMAX NVDA OPTION INCOME STRATEGY ETF","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","NVDS.UK":"LS -1X NVIDIA","LU2420271590.USD":"ALLIANZ SELECT INCOME AND GROWTH \"AT\" (USD) ACC","BK4592":"伊斯兰概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC"},"translate_title":"生物技术龙头ADMA从意外暴跌中恢复后触及新买入点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"ATAT":1,"RYTM":1,"NVD3.UK":0.6,"NVD":0.6,"NVD2.UK":0.6,"NVDD":0.6,"NVDS":0.6,"NVDS.UK":0.6,"NVDU":0.6,"NVDX":0.6,"NVDY":0.6,"SNVD.UK":0.6,"3NVD.UK":0.6,"2NVD.UK":0.6},"content_text":"Tuesday's IBD 50 Stocks To Watch pick is biotech stock ADMA Biologics (ADMA), which is back above a recent buy point. ADMA stock is also the No. 1-ranked stock on the IBD 50 list, which makes it one of the best ideas to watch right now.\nThe company develops specialty plasma-derived human immune globulin, essentially blood protein products. The treatments are used to prevent and treat infectious diseases in patients with immunodeficiencies.\n\n\n\n↑\nX\n\n\n\n\nThe Interesting Truth Behind Today's Market Sentiment And How To Find Growth\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nThe Interesting Truth Behind Today's Market Sentiment And How To Find Growth\n\n\n\n\nThe biopharmaceutical company has three products approved by the Food and Drug Administration. It is developing a pneumonia biologic and has an ongoing pediatric clinical study for Asceniv.\nAsceniv is a cocktail created from super donors whose plasma contains a high level of antibodies capable of handling respiratory syncytial virus, or RSV. RSV is a seasonal virus that can be serious or even deadly in people with insufficient immune systems, particularly newborns and older adults. Demand for Asceniv has skyrocketed, thanks to its strong effectiveness.\nOn Oct. 10, ADMA stock crashed more than 16% after the company's auditor unexpectedly resigned. That triggered a key sell signal, but shares have quickly recovered from those losses. In early November, ADMA completed a deal with KPMG, which signed on as its new independent registered public accounting firm.\nIts latest quarterly results, reported on Nov. 8, showed adjusted earnings of 15 cents per share, above expectations for 13 cents. Earnings skyrocketed from a 1-cent gain in the year-earlier period. Sales also surged 78% to $119.8 million, beating forecasts for $105.8 million.\nFor the full year, Wall Street forecasts the company to earn 52 cents per share, with growth of 38% to 72 cents in 2025, per IBD MarketSurge.\n\nThis Industry Group — And 4 IPOs — Polish 20 'Perfect' Gems\n\n\nADMA Stock At Buy Point\nOn Nov. 8, ADMA stock broke out past a short cup base's 21.13 buy point, but shares quickly pulled back below the buy point. In recent sessions, they found much-needed support at the 50-day moving average line.\nNow, ADMA stock is rebounding from that level and is back above the buy point. The 5% buy range goes up to 22.19.\nBullishly, the stock's relative strength line hit a new high in recent weeks. That confirms shares are beating the performance of the S&P 500.\nAmid powerful gains in recent years, ADMA stock boasts a best-possible 99 Composite Rating from Investor's Business Daily, according to IBD Stock Checkup.\n\nCracks Emerge In Nvidia's AI Armor. What's An Investor To Do?\n\nOther Stocks To Keep An Eye On\nThree recent IBD 50 Growth Stocks To Watch picks are among the best stocks to buy and watch.\n\n\n\nCompany\nSymbol\n Buy point\nType of base\n\n\n\n\nAtour Lifestyle\n (ATAT)\n29.15\nConsolidation\n\n\nGeneDx\n (NVDA)\n89.11\nConsolidation\n\n\nRhythm Pharmaceuticals\n (RYTM)\n55.64\nConsolidation\n\n\n\nSource: IBD Data as of Nov. 26\nFollow Scott Lehtonen on X at @IBD_SLehtonen for more on the best stocks to buy and watch and the Dow Jones Industrial Average.\nYOU MAY ALSO LIKE:\nIBD's New Exposure Levels\nTop Growth Stocks To Buy And Watch\nLearn How To Time The Market With IBD's ETF Market Strategy\nFind The Best Long-Term Investments With IBD Long-Term Leaders\nSpot Buy Points And Sell Signals With MarketSurge Pattern Recognition","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486004585"}